机构:[1]Department of Clinical Pharmacy, TheSecond Affiliated Hospital, GuangzhouUniversity of Chinese Medicine, Guangzhou,Guangdong, P.R. China[2]Postdoctoral Scientific Research ofGuangzhou University of Chinese Medicine,Guangzhou, Guangdong, P.R. China[3]School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine,Guangzhou, Guangdong, P.R. China[4]Department of Nephrology, The SecondAffiliated Hospital, Guangzhou University ofChinese Medicine, Guangzhou, Guangdong,P.R. China深圳市中医院深圳医学信息中心[5]Section of Immunology & Chinese Medicine,The Second Affiliated Hospital of GuangzhouUniversity of Chinese, Guangzhou,Guangdong, P.R. China
The main pathological characteristics of chronic glomerulonephritis (CGN) are diffuse mesangial cells proliferation and inflammatory responses. Our previous studies have confirmed that miR-145-5p was abnormally elevated in CGN rats, but its mechanism remains unclear. Therefore, this study aimed to elucidate the mechanism of miR-145-5p in regulation of renal mesangial cells proliferation and inflammatory responses. In vivo study, the cationic bovine serum albumin (C-BSA)-induced CGN rat model was established, and the content of miR-145-5p in renal was examined by qRT-PCR, meanwhile, we also determined the renal function and inflammatory infiltrate. In vitro, the cell proliferation rate, cell cycle and inflammatory changes of rat mesangial cells (RMCs) were measured. Our results suggested that miR-145-5p extended the G0-G1 phase, shortened S phase, inhibited cell proliferation and suppressed inflammatory responses in RMCs. Moreover, miR-145-5p inhibited CXCL16 protein expression through binding the 3-UTR of CXCL16, suppressed AKT/GSK signaling pathway, and decreased expression of inflammation related mRNAs, such as IL-1, IL-2, IL-6, and TNF- mRNAs. Further, locking CXCL16 alleviated inflammatory reactions and down-regulated AKT/GSK pathway in RMCs. Above all, we concluded that miR-145-5p inhibited proliferation and inflammatory responses of RMCs through regulation of AKT/GSK pathway by targeting CXCL16.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81603371, 81673874]; National Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030310292, 2014A020210024]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M612645]; TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YN2016YX04]
第一作者机构:[1]Department of Clinical Pharmacy, TheSecond Affiliated Hospital, GuangzhouUniversity of Chinese Medicine, Guangzhou,Guangdong, P.R. China[2]Postdoctoral Scientific Research ofGuangzhou University of Chinese Medicine,Guangzhou, Guangdong, P.R. China
通讯作者:
通讯机构:[3]School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine,Guangzhou, Guangdong, P.R. China[*1]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China.
推荐引用方式(GB/T 7714):
Wu Junbiao,He Yu,Luo Yining,et al.MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16[J].JOURNAL OF CELLULAR PHYSIOLOGY.2018,233(4):3648-3659.doi:10.1002/jcp.26228.
APA:
Wu, Junbiao,He, Yu,Luo, Yining,Zhang, Lei,Lin, Hua...&Zhou, Jiuyao.(2018).MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16.JOURNAL OF CELLULAR PHYSIOLOGY,233,(4)
MLA:
Wu, Junbiao,et al."MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16".JOURNAL OF CELLULAR PHYSIOLOGY 233..4(2018):3648-3659